Find Faculty Members at MUSC.

Jacqueline M Kraveka DO

Provider Image

(843) 792-2957

kravekjm@musc.edu

125 Doughty Street, MSC 917,Charleston, SC 29403

Faculty email addresses should not be used to seek medical advice or to make medical appointments. Please visit MyChart for medical appointments or to contact your provider.
Rank
  • Professor
College
  • College of Medicine
Department
  • Pediatrics
Academic Focus
  • Pediatric Oncology
  • Neuroblastoma, pediatric sarcomas, pediatric precision medicine and clinical trial development
  • Research on Bioactive Sphingolipids in Pediatric Malignancies
Faculty email addresses should not be used to seek medical advice or to make medical appointments. Please visit MyChart for medical appointments or to contact your provider.

Locations

Office Location
street
room

Biography

Education & Training:

 Columbia University, Columbia College, 1989 B.A.

Nova Southeastern University, College of Osteopathic Medicine, 1994 D.O.
Miami Children's Hospital, 1995-1997, Residency in Pediatrics
Medical University of South Carolina, 1997-2000, Fellowship in Pediatric Hematology-Oncology

Research Interests:

Dr. Kraveka’s clinical practice is focused on pediatric oncology.  Her clinical interests are in neuroblastoma, pediatric sarcomas, pediatric precision medicine and clinical trial development.  

 

She is actively involved in clinical pediatric research in the Beat Childhood Cancer Research Consortium (BCC) where she is a member of the Executive Board and Scientific Committee. Dr. Kraveka was part of the core BCC team that designed and conducted the clinical trials that led to the FDA approval of IWILFIN™ (eflornithine) in December 2023. IWILFIN™ is the first oral maintenance treatment approved to reduce the risk of relapse in patients with high-risk neuroblastoma. 

 

Dr. Kraveka serves as the Institutional Principal Investigator for Children’s Oncology Group and BCC clinical trials at MUSC. As the Institutional PI, she has been responsible for the conduct of over 80 Biology, Phase I, Phase II and Phase III clinical trials at MUSC. She has designed and serves as the national Study Chair for BCC018: A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma for children with newly diagnosed high-risk neuroblastoma (NCT05489887). This trial employs the novel approach of incorporating anti-GD2 immunotherapy with the antibody naxitamab with upfront chemotherapy. 

 

 In addition to clinical research, Dr. Kraveka is also involved in translational and bench research. Dr. Kraveka’s current research focuses on sphingolipid mediated therapies in pediatric cancers in pediatric cancer. The long-term goals of her research are to develop more effective treatments for children with cancer. 

 

Some of current research projects include:

  •  Precision Medicine for Neuroblastoma, Rare Tumors and Relapsed/Refractory Pediatric Cancers
  • Identification of new biomarkers in neuroblastoma
  •  Development of novel inhibitors to DEGS-1 for pediatric cancer therapy
  •  Examining the role ceramide synthases in high-risk neuroblastoma
  •  Evaluation of sphingosine kinase inhibitors in pediatric cancers

 

 Highlight Publications:

  1. Sholler GLS, Bergendahl G, Lewis EC, Kraveka J, Ferguson W, Nagulapally AB, Dykema K, Brown VI, Isakoff MS, Junewick J, Mitchell D, Rawwas J, Roberts W, Eslin D, Oesterheld J, Wada RK, Pastakia D, Harrod V, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna GK, Enriquez D, Izatt T, Halperin RF, Moore A, Byron SA, Hendricks WPD, Trent JM. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial. Genome Med. 2024 Feb 12;16(1):28. 
  2.  
  3. Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol. 2023 Oct 26. Epub ahead of print. 
  4.  
  5. Kraveka JM, Lewis EC, Bergendahl G, Ferguson W, Oesterheld J, Kim E, Nagulapally AB, Dykema KJ, Brown VI, Roberts WD, Mitchell D, Eslin D, Hanson D, Isakoff MS, Wada RK, Harrod VL, Rawwas J, Hanna G, Hendricks WPD, Byron SA, Snuderl M, Serrano J, Trent JM, Saulnier Sholler GL. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma. Cancer Rep (Hoboken). 2022 Mar 31:e1616. 
  6.  
  7. Byron SA, Hendricks WPD, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W, Isakoff MS, Oesterheld JE, Wada RK, Rawwas J, Neville K, Zage PE, Harrod VL, Bergendahl G, VanSickle E, Dykema K, Bond J, Chou HC, Wei JS, Wen X, Reardon HV, Roos A, Nasser S, Izatt T, Enriquez D, Hegde AM, Cisneros F, Christofferson A, Turner B, Szelinger S, Keats JJ, Halperin RF, Khan J, Saulnier Sholler GL, Trent JM. Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. Cancer Res. 2021 Dec 1;81(23):5818-5832 
  8.  
  9. Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer. 2020 Dec 1;147(11):3152-3159.